| Revenue | 957.09a | 898.6a |
| Cost of sales | -634.48a | -582.11a |
| Gross profit | 322.61a | 316.49a |
| Selling expenses | -79.84a | -79.16a |
| General administrative expenses | -44.63a | -42.93a |
| Research and development costs | -24.25a | -26.82a |
| Other operating income | 26.4a | 25.74a |
| Other operating expenses | -20.19a | -12.68a |
| Share of profit from investments accounted for using the equity method | 12.49a | 11.74a |
| Operating income (EBIT) | 192.58a | 192.38a |
| Interest income | 5.96a | 5.23a |
| Interest expenses | -13.49a | -7.25a |
| Net other financial result | -1.08a | -4.55a |
| Financial result | -8.61a | -6.58a |
| Profit before income taxes | 183.97a | 185.8a |
| Income tax expenses | -33.63a | -33.87a |
| Profit for the period | 150.35a | 151.93a |
| Thereof attributable to non-controlling interests | 0.66a | 0.09a |
| Thereof attributable to limited liability shareholders of SCHOTT Pharma AG & Co. KGaA | 149.69a | 151.84a |